CTOs on the Move

Erba Diagnostics

www.erbadiagnostics.com

 
ERBA Diagnostics Inc., is a part of the global ERBA Mannheim Group. Earlier known by the name of IVAX Diagnostics, the company specializes in manufacture and marketing of proprietary diagnostic reagents, test kits and instrumentation in the areas of autoimmune, chemistry, hematology, diabetes and infectious diseases. ERBA Diagnostics has further strengthened ERBA Group`s comprehensive portfolio of instrument and reagent solutions, covering all levels of automation and throughput needs of laboratories across the world. With its team of experienced marketing, technical and service professionals and a strong and extensive distribution network the company lives up to the ERBA Group`s philosophy of consistently delivering ...
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Synergetics USA, Inc

Synergetics USA, Inc. (Synergetics USA) designs, manufactures and markets microsurgical instruments, medical capital equipment and other medical devices primarily for use in ophthalmic surgery and neurosurgical applications.

Texas American Title Company

Texas American Title Company is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in New York, NY. To find more information about Texas American Title Company, please visit www.texasamerican.com

Southern Cord

Southern Cord is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Health Care Software

American Health Care Software is a South Burlington, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cardionomic

Unlike traditional approaches that only address symptoms, Cardionomic addresses the conditions root cause of reduced contractility. The therapy uses neuromodulation to benignly increase contractility, thus improving cardiac output therefore increasing renal flow and end organ perfusion. Benignly increasing contractility decreases negative hormonal signaling, and improves in-hospital morbidity/mortality. This breakthrough therapy is also expected to increase pharmacological tolerance at discharge, which will reduce costly readmission and extend life. Spun off from Denali Medical II, a New Enterprise Associates (NEA) backed incubator, Cardionomic is funded by NEA, Greatbatch Medical and Cleveland Clinic Foundation.